Hyperlipidemia, tissue factor, coagulation, and simvastatin

Trends in Cardiovascular Medicine

Volumn 24, Issue 3, 2014, Pages 95-98

  Owens, Albert Phillip ^a   Byrnes, James Robert ^a   Mackman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMATOPOIETIC CELL DERIVED TISSUE FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DRUG EFFECT; FAMILIAL HYPERLIPEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; LEUKOCYTE; MONOCYTE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STUDY; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; SIMVASTATIN; THROMBOPLASTIN; THROMBOSIS;

EID: 84896738743     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2013.07.003     Document Type: Review

References (45)

1. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103(2):276-283.
2. Albert M.A., Danielson E., Rifai N., Ridker P.M., Investigators P. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc 2001, 286(1):64-70.
3. Bea F., Blessing E., Shelley M.I., Shultz J.M., Rosenfeld M.E. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003, 167:187-194.
4. Bochkov V.N., Mechtcheriakova D., Lucerna M., Huber J., Malli R., Graier W.F., et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 2002, 99:199-206.
5. Boullier A., Bird D.A., Chang M.K., Dennis E.A., Friedman P., Gillotre-Taylor K., et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Annals of the New York Academy of Sciences 2001, 947:214-222. ([discussion 222-213]).
6. Casani L., Sanchez-Gomez S., Vilahur G., Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thrombosis and Haemostasis 2005, 94(5):1035-1041.
7. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 1997, 17:265-272.
8. Cui M.Z., Penn M.S., Chisolm G.M. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. Journal of Biological Chemistry 1999, 274(46):32795-32802.
9. Di Garbo V., Bono M., Di Raimondo D., De Simone R., Raneli G., Avellone G. Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response. European Journal of Clinical Pharmacology 2000, 56(4):277-284.
10. Diaz J.A., Ballard-Lipka N.E., Farris D.M., Hawley A.E., Wrobleski S.K., Myers D.D., et al. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. Journal of Vascular Surgery 2012, 55(3):815-822.
11. Drake T.A., Hannani K., Fei H.H., Lavi S., Berliner J.A. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. American Journal of Pathology 1991, 138(3):601-607.
12. Eitzman D.T., Westrick R.J., Xu Z., Tyson J., Ginsburg D. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20(7):1831-1834.
13. Eto M., Kozai T., Cosentino F., Joch H., Luscher T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002, 105(15):1756-1759.
14. Ferro D., Basili S., Alessandri C., Cara D., Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000, 149:111-116.
15. Ferro D., Basili S., Alessandri C., Mantovani B., Cordova C., Violi F. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet 1997, 350:1222.
16. Glynn R.J., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. New England Journal of Medicine 2009, 360(18):1851-1861.
17. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013, 127:e6-e245.
18. Guha M., Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. Journal of Biological Chemistry 2002, 277(35):32124-32132.
19. Kadl A., Huber J., Gruber F., Bochkov V.N., Binder B.R., Leitinger N. Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. Vascular Pharmacology 2002, 38:219-227.
20. Kunjathoor V.V., Febbraio M., Podrez E.A., Moore K.J., Andersson L., Koehn S., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. Journal of Biological Chemistry 2002, 277(51):49982-49988.
21. Leroyer A.S., Isobe H., Leseche G., Castier Y., Wassef M., Mallat Z., et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. Journal of the American College of Cardiology 2007, 49(7):772-777.
22. Levitan I., Volkov S., Subbaiah P.V. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxidants & Redox Signaling 2010, 13:39-75.
23. Liao J.K., Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005, 45:89-118.
24. Mackman N. The many faces of tissue factor. Journal of Thrombosis and Haemostasis 2009, 7(Suppl. 1):136-139.
25. Mackman N., Brand K., Edgington T.S. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. Journal of Experimental Medicine 1991, 174(6):1517-1526.
26. Matsumoto N., Nomura S., Kamihata H., Kimura Y., Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thrombosis and Haemostasis 2004, 91:146-154.
27. Meisel S.R., Xu X.-P., Edgington T.S., Cercek B., Ong J., Kaul S., et al. Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. Journal of Atherosclerosis and Thrombosis 2011, 18:596-603.
28. + monocytes. Arteriosclerosis, Thrombois, and Vascular Biology 2005, 25:1439-1445.
29. Methe H., Kim J.-O., Kofler S., Weis M., Nabauer M., Koglin J. Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005, 111:2654-2661.
30. Monetti M., Canavesi M., Camera M., Parente R., Paoletti R., Tremoli E., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacological Research 2007, 55:441-449.
31. Morel O., Pereira B., Averous G., Faure A., Jesel L., Germain P., et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis 2009, 204:636-641.
32. Nagata K., Ishibashi T., Sakamoto T., Ohkawara H., Shindo J., Yokoyama K., et al. Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. Atherosclerosis 2002, 163(1):39-47.
33. Owens A.P., Mackman N. Microparticles in hemostasis and thrombosis. Circulation Research 2011, 108:1284-1297.
34. Owens A.P., Mackman N. Role of tissue factor in atherothrombosis. Current Atherosclerosis Reports 2012, 14:394-401.
35. Owens A.P., Passam F.H., Antoniak S., Marshall S.M., McDaniel A.L., Rudel L., et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. Journal of Clinical Investigation 2012, 122:558-568.
36. Patterson K.A., Zhang X., Wrobleski S.K., Hawley A.E., Lawrence D.A., Wakefield T.W., et al. Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thrombosis Research 2013, 131(3):268-276.
37. Podrez E.A., Byzova T.V., Febbraio M., Salomon R.G., Ma Y., Valiyaveettil M., et al. Platelet CD36 links hyperlipidemia, oxidant stress, and a prothrombotic phenotype. Nature Medicine 2007, 13(9):1086-1095.
38. Puccetti L., Bruni F., Bova G., Cercignani M., Pompella G., Auteri A., et al. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. International Journal of Clinical & Laboratory Research 2000, 30:147-156.
39. Rosenson R.S. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004, 173(1):1-12.
40. Ross R. Atherosclerosis-an inflammatory disease. New England Journal of Medicine 1999, 340:115-126.
41. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., et al. CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer. Nature Immunology 2010, 11:155-161.
42. Sukhova G.K., Williams J.K., Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22(9):1452-1458.
43. Tsimikas S., Witztum J.L., Miller E.R., Sasiela W.J., Szarek M., Olsson A.G., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004, 110(11):1406-1412.
44. Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proceedings of the National Academy of Sciences of the United States of America 1989, 86(8):2839-2843.
45. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.